Concurrent chemoradiation treatment at high-volume facilities improves survival for non-small cell lung cancer patients.
Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.
A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient’s molecular and clinical characteristics by providing feedback from an expert panel.
Mesothelioma in young people and women in southern Nevada likely the result of asbestos in the environment
Malignant mesothelioma has been found at higher than expected levels in women and in individuals younger than 55 years old in the southern Nevada counties of Clark and Nye, likewise in the same region carcinogenic mineral fibers including actinolite asbestos, erionite, winchite, magnesioriebeckite and richterite were discovered. These data, published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, suggest that these elevated numbers of malignant mesothelioma cases are linked to environmental exposure of carcinogenic mineral fibers.
The Dutch-Belgian NELSON lung cancer screening trial results are inferable for the general high-risk population.
Results of the NELSON lung cancer screening trial using low dose computed tomography (LDCT) can be used to predict the effect of population-based screening on the Dutch population even though there were slight differences in baseline characteristics of participants in the control arm versus eligible non-participants.
Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common “classical” EGFR mutations. However, as not all rare mutations are the same, testing and therapy may need to be evaluated for each individual mutation.
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.